Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | APAF1 | O14727 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.59 |
| ▸ | FDPS | P14324 | 17/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1735067 | 1.00 | MEN1 (0.59) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL1736115 | 1.00 | MEN1 (0.59) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL358008 | 1.00 | MEN1 (0.59) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL1736110 | 1.00 | MEN1 (0.59) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL1858368 | 1.00 | MEN1 (0.59) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL357140 | 0.95 | MEN1 (0.51) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| SCHEMBL16107838 | 0.90 | MEN1 (0.43) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| Trifluoromethanesulfonic Acid SCHEMBL318764 | 0.89 | MEN1 (0.68) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| Trifluoromethanesulfonic Acid SCHEMBL1331129 | 0.89 | MEN1 (0.68) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 | |
| Trifluoromethanesulfonic Acid SCHEMBL318767 | 0.89 | MEN1 (0.68) | MEN1HSP90AA1KMT2ASMN1; SMN2APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021276-B1 | PROCESS FOR PURIFYING PERFLUORINATED PRODUCTS | DU PONT (US) | 2013-07-17 | — | — | EP | claimed |
| US-20200129922-A1 | METHOD OF REDUCING CONCENTRATION OF FLUORINE-CONTAINING COMPOUND IN SAMPLE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-04-30 | — | — | US | disclosed |
| US-8771626-B2 | Process for purifying perfluorinated products | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-07-08 | — | — | US | disclosed |
| US-8715521-B2 | Absorption cycle utilizing ionic liquid as working fluid | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8707720-B2 | Hybrid vapor compression-absorption cycle | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-04-29 | — | — | US | disclosed |
| US-8628644-B2 | Utilizing ionic liquids for hydrofluorocarbon separation | E I DU PONT NEMOURS AND COMPANY (US) | 2014-01-14 | — | — | US | disclosed |
| US-8568608-B2 | Vapor compression cycle utilizing ionic liquid as compressor lubricant | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2021276-B1 | PROCESS FOR PURIFYING PERFLUORINATED PRODUCTS | DU PONT (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-1846535-B1 | ABSORPTION CYCLE UTILIZING IONIC LIQUID AS WORKING FLUID | DU PONT (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2368960-A1 | Vapor compression utilizing ionic liquid as compressor lubricant | E. I. du Pont de Nemours and Company (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100257879-A1 | HYBRID VAPOR COMPRESSION-ABSORPTION CYCLE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-10-14 | — | — | US | disclosed |
| US-7765823-B2 | Cooling or heating systems using refrigerants and absorbentssuch as fluorocarbon gases in fluorinated ionic liquids;comprising an absorber, generator, condenser, pressure reductiondevice, evaporator, compressor, and conduit fromm the evaporator tothe absorber; efficiency | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-08-03 | — | — | US | disclosed |
| EP-2027225-A2 | VAPOR COMPRESSION UTILIZING IONIC LIQUID AS COMPRESSOR LUBRICANT | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20070295478-A1 | Vapor Compression Cycle Utilizing Ionic Liquid as Compressor Lubricant | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-12-27 | — | — | US | disclosed |
| US-20070297965-A1 | PROCESS FOR PURIFYING PERFLUORINATED PRODUCTS | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-12-27 | — | — | US | disclosed |
| WO-2007143051-A2 | VAPOR COMPRESSION UTILIZING IONIC LIQUID AS COMPRESSOR LUBRICANT | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20070131535-A1 | Utilizing ionic liquids for hydrofluorocarbon separation | THE CHEMOURS COMPANY FC, LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070019708-A1 | Hybrid vapor compression-absorption cycle | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-01-25 | — | — | US | disclosed |
| US-20060197053-A1 | Absorption cycle utilizing ionic liquid as working fluid | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070131535-A1 | Utilizing ionic liquids for hydrofluorocarbon separation | AQP3, AQP1, SLC26A3 | MEN1 995/4885HSP90AA1 631/4885KMT2A 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.